De Aller-Bedste Bøger - over 12 mio. danske og engelske bøger
Levering: 1 - 2 hverdage
Hjælp
Login
  1. Forside
  2. Bøger
  3. Business og læring
  4. Økonomi og finans
  5. The Pharmagellan Guide to Biotech Forecasting and Valuation

The Pharmagellan Guide to Biotech Forecasting and Valuation

af Andrew Matthews, Frank S David, Seth Robey
The Pharmagellan Guide to Biotech Forecasting and Valuation af Andrew Matthews
Bag om The Pharmagellan Guide to Biotech Forecasting and Valuation

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser-or aspire to be one-then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies. • Vetted benchmarks for key drivers of income, expenses, and valuation. • Proprietary analyses by Pharmagellan's experienced consulting team. • More than 150 current references from peer-reviewed research, industry white papers, and SEC filings. Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.

Vis mere
  • Sprog:
  • Engelsk
  • ISBN:
  • 9780998407500
  • Indbinding:
  • Paperback
  • Sideantal:
  • 138
  • Udgivet:
  • 6. januar 2017
  • Størrelse:
  • 228x151x14 mm.
  • Vægt:
  • 222 g.
  • 2-3 uger.
  • 2. december 2024

Normalpris

Abonnementspris

- Rabat på køb af fysiske bøger
- 1 valgfrit digitalt ugeblad
- 20 timers lytning og læsning
- Adgang til 70.000+ titler
- Ingen binding

Abonnementet koster 75 kr./md.
Ingen binding og kan opsiges når som helst.

Bag om Andrew Matthews

Vis alle bøger af Andrew Matthews

Beskrivelse af The Pharmagellan Guide to Biotech Forecasting and Valuation

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser-or aspire to be one-then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.
THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.
• Vetted benchmarks for key drivers of income, expenses, and valuation.
• Proprietary analyses by Pharmagellan's experienced consulting team.
• More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.
Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.

Brugerbedømmelser af The Pharmagellan Guide to Biotech Forecasting and Valuation



Andre købte også..
Find lignende bøger
Bogen The Pharmagellan Guide to Biotech Forecasting and Valuation findes i følgende kategorier: